Last reviewed · How we verify
Sordinol (CLOPENTHIXOL)
Sordinol (generic name: CLOPENTHIXOL) is a clopenthixol drug. It is currently in Phase 2 development for Psychotic disorder.
Sordinol works by blocking the 5-hydroxytryptamine receptor 6, which helps to regulate mood and behavior.
Sordinol (Clopenthixol) is a small molecule drug belonging to the clopenthixol class, targeting the 5-hydroxytryptamine receptor 6. It is used to treat psychotic disorders. The commercial status of Sordinol is unclear, and it may be patented or have generic manufacturers. Key safety considerations are not well-documented. As a result, its use should be approached with caution.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | CLOPENTHIXOL |
|---|---|
| Drug class | clopenthixol |
| Target | 5-hydroxytryptamine receptor 6 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | Phase 2 |
Mechanism of action
Think of it like a volume control on a radio. The 5-hydroxytryptamine receptor 6 is like a dial that helps control how much of a certain signal is sent to the brain. By blocking this dial, Sordinol helps to reduce the amount of signal sent, which can help to calm the brain and reduce symptoms of psychosis.
Approved indications
- Psychotic disorder
Common side effects
Key clinical trials
- Long-acting Injectable Antipsychotics for Mental Ill-Health in Pregnancy and Postpartum
- Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR. (PHASE4)
- Study Comparing Antipsychotic Dose Reduction vs. Maintenance Treatment in Patients With Schizophrenia Spectrum Disorder: a Personalized Medicine Approach (PHASE2)
- Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients (PHASE4)
- Pharmacovigilance in Gerontopsychiatric Patients (PHASE3)
- Antipsychotics and Risk of Hyperglycemic Emergencies
- Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis (PHASE3)
- Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sordinol CI brief — competitive landscape report
- Sordinol updates RSS · CI watch RSS
Frequently asked questions about Sordinol
What is Sordinol?
How does Sordinol work?
What is Sordinol used for?
What is the generic name of Sordinol?
What drug class is Sordinol in?
What development phase is Sordinol in?
What does Sordinol target?
Related
- Drug class: All clopenthixol drugs
- Target: All drugs targeting 5-hydroxytryptamine receptor 6
- Therapeutic area: All drugs in Neuroscience
- Indication: Drugs for Psychotic disorder
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing